๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Acute Adult T-Cell Leukemia/Lymphoma

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL NCT06481228NA1 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: CAR-T cells, Venetoclax, Olverembatinib VHAG in Treating R/R T-ALL/LBL NCT06742463Phase 21 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: Venetoclax, homoharringtonine, Cytarabine (Ara-C), G-CSF Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946Phase 1, Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: CD5-targeted CAR-T cells CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia NCT07328503Phase 21 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia NCT07361029Phase 11 site๐Ÿ“ Riyadh King Faisal Specialist Hospital & Research Center ยท Tests: CAR T cells chimeric antigen receptor cells Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations NCT07012447Phase 21 site๐Ÿ“ Suzhou yuejun Liu ยท Tests: Venetoclax, Azacitidine, Cytarabine Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies NCT07648264Phase 360 sites๐Ÿ“ Orange๐Ÿ“ Denver๐Ÿ“ Coral Springs CSL Behring ยท Tests: IgPro20 Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia NCT06446661NA1 site๐Ÿ“ Chicago University of Chicago ยท Tests: High Intensity, No Text Messagings, Low Intensity Text Messaging A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) NCT06207123Phase 1, Phase 22 sites๐Ÿ“ Chicago๐Ÿ“ Rochester University of Chicago ยท Tests: LP-118, Ponatinib, Vincristine, Dexamethasone, Methotrexate MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ฮถ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) NCT03938987Phase 1, Phase 26 sites๐Ÿ“ Calgary๐Ÿ“ Calgary๐Ÿ“ Calgary University of Alberta ยท Tests: autologous CD19-directed chimeric antigen receptor (CAR) T-cells Determining the Mechanisms of Loss of CAR T Cell Persistence NCT05809284n/a3 sites๐Ÿ“ London๐Ÿ“ London๐Ÿ“ Manchester University College, London Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies NCT07312630EARLY Phase 11 site๐Ÿ“ Hefei PersonGen BioTherapeutics (Suzhou) Co., Ltd. ยท Tests: LV009 Injection Infusion HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant NCT03326921Phase 11 site๐Ÿ“ Seattle Fred Hutchinson Cancer Center ยท Tests: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) NCT06561074Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Decitabine, Venetoclax, Calaspargase pegol-mknl CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia NCT05043571Phase 11 site๐Ÿ“ Singapore National University Hospital, Singapore ยท Tests: CAR T-cell therapy A Study of CTD402 in T-ALL/LBL Patients NCT07070219Phase 1, Phase 29 sites๐Ÿ“ Palo Alto๐Ÿ“ Denver๐Ÿ“ Chicago Imviva Bio ยท Tests: CTD402 CAR T Cell Injection Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Senl_B19 autologous CAR-T (S1904) treatment CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies NCT05442515Phase 1, Phase 21 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 NCT05535855Phase 11 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19 Directed CAR T Cell TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL NCT06481735Phase 1, Phase 26 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Beijing Chinese PLA General Hospital ยท Tests: TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell, Fludarabine, Cyclophosphamide SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies NCT07153068Phase 1, Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: supCD7 CART cells A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph... NCT05621291NA8 sites๐Ÿ“ Los Angeles๐Ÿ“ Washington D.C.๐Ÿ“ Atlanta National Cancer Institute (NCI) ยท Tests: NGS testing Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). NCT06213636Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: CD19/CD22-CAR T cells The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors NCT06911710Phase 1, Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University General Hospital ยท Tests: CAR-T Cells infusion๏ผˆCAR2219,CAR2019, CAR19 etc๏ผ‰ Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) NCT04301076Phase 119 sites๐Ÿ“ Atlanta๐Ÿ“ Atlanta๐Ÿ“ City of Saint Peters National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR NCT03676504Phase 1, Phase 22 sites๐Ÿ“ Heidelberg๐Ÿ“ Heidelberg University Hospital Heidelberg ยท Tests: CD19.CAR T Cells, Fludarabine, Cyclophosphamide Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study NCT07072494Phase 1, Phase 22 sites๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Zhujiang Hospital ยท Tests: CD19 CAR-T cells injection
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy